Highest-materiality recent filing
ATEC Q2 revenue $214M (+15% YoY); raises FY2026 adjusted EBITDA guidance to $140M
Total revenue $214M (+15% YoY); surgical revenue $196M (+17% YoY) on 20% case volume growth.
Alphatec shareholders approve 2026 equity incentive and ESPP plans
Stockholders approved 2026 Equity Incentive Plan (66.3M For, 28.1M Against) and 2026 Employee Stock Purchase Plan (94.5M For).
ATEC Q1 rev $192M (+14%), surgical rev +17%; refinances debt with bank facility saving >$6M/yr
Q1 total revenue $192M (14% YoY growth); surgical revenue $178M (+17%) driven by 21% case volume growth.
Alphatec FY2025 revenue $764M (+25% YoY); guides FY2026 ~$890M, raises EBITDA guidance
Full-year 2025 total revenue $764M (+25% YoY); GAAP net loss $143M; non-GAAP net income $8M.
ATEC prelim FY2025 rev ~$764M (+25%), FY2026 outlook $890M; acquires OsteoAdapt distribution rights
Preliminary FY2025 total revenue ~$764M (25% growth); surgical revenue grew 26% with volume up 24%.
ATEC reports Q3 revenue $197M (+30% YoY), raises FY2025 guidance to $760M
Total revenue $197M, surgical revenue $177M (+31% YoY); EOS revenue $20M (+29%).
ATEC Q2 revenue $186M (+27.5% YoY), raises FY revenue and EBITDA guidance
Surgical revenue $168M (+29% YoY); total revenue $186M (+27.5% YoY).
ATEC Q1 revenue $169M (+22% YoY); raises FY guidance to $734M; refinances convertible debt to 2030
Surgical revenue $152M (+24%), driven by 17% procedural volume growth and 18% new surgeon adoption increase.
Alphatec issues $405M 0.75% convertibles due 2030, repurchases $253M of 2026 notes
Completed repurchase of $253.0M of its 0.75% convertible senior notes due 2026 on March 10, 2025.
Alphatec issues $405M 0.75% convertible notes due 2030; repurchases $253M 2026 notes
Issued $405M principal of 0.75% Convertible Senior Notes due 2030, including $55M from full exercise of initial purchasers' option.
ATEC prices upsized $350M 0.75% convertible notes due 2030; to repurchase $253M 2026 notes
Pricing of $350M principal (upsized from $300M) of 0.75% convertible senior notes due 2030; initial conversion price ~$15.54 (32.5% premium).
Alphatec announces $300M convertible notes offering due 2030, repurchases part of 2026 notes
Offers $300M aggregate principal of convertible senior notes due 2030; initial purchasers option for additional $50M.
ATEC FY2024 revenue $612M (+27% YoY); guides FY2025 rev ~$732M, positive FCF
FY2024 total revenue $612M, +27% YoY; GAAP net loss $162M; non-GAAP adjusted EBITDA $31M (5% margin).
Alphatec reports prelim 2024 rev ~$611M (+27% YoY); guides 2025 rev $732M, positive FCF
Preliminary full-year 2024 total revenue ~$611M (+27% YoY); surgical revenue up 29% to ~$544M.
ATEC Q3 revenue $151M (+27%), raises FY guidance, adds $50M term loan
Q3 total revenue $151M, up 27% YoY; surgical revenue grew 30%.
ATEC Q2 revenue $146M (+25% YoY); raises FY2024 guidance to $602M rev, ~$25.5M adj EBITDA
Total revenue $146M (+25% YoY); surgical revenue +27%. GAAP net loss $41M; adjusted EBITDA $5.6M (4% margin).
ATEC Q1 revenue up 27% to $138M; raises FY 2024 guidance
Surgical revenue grew 30% YoY on 23% volume increase and 6% higher average revenue per procedure.
Alphatec reports FY2023 revenue $482M (+37% YoY); guides FY2024 revenue ~$595M
Full-year 2023 revenue $482M, up 37% YoY; Q4 revenue $138M, surgical revenue growth 34%.
Record preliminary 2023 revenue ~$481M (+37% YoY); 2024 guidance $595M
Preliminary FY2023 total revenue $481.1-482.7M, up ~37% YoY; surgical revenue grew 39-40%.
ATEC Q3 revenue up 32% to $118M; raises FY2023 adjusted EBITDA guidance to ~$3M
Total revenue $118M (+32% YoY); surgical revenue $104M (+32%), EOS $14M (+30%).
Alphatec Holdings prices $150M public offering of 14.3M shares at $10.50 each
Gross proceeds of ~$150M from 14.3M shares at $10.50; underwriters have 30-day option for 2.145M more.
ATEC launches $150M stock offering; preliminary Q3 shows improved adjusted EBITDA
Proposed underwritten public offering of $150M common stock; underwriters have 30-day option to buy additional $22.5M.
Alphatec appoints former Globus Medical CEO Demski to board, Valentine as special advisor
Dave Demski, former Globus Medical CEO (2017-2022), appointed independent director effective Oct 17, 2023.
ATEC raises FY2023 revenue guidance to ~$472M after Q3 preliminary revenue of $117.7-118.5M
Q3 total revenue $117.7-118.5M (+31-32% YoY), driven by lateral adoption momentum.
ATEC Q2 revenue up 39% to $117M; raises FY2023 revenue guidance to $462M and adjusted EBITDA to ~$2M
Total revenue $117M (+39% YoY); surgical revenue $102M (+41%), EOS revenue $15M (+24%).
Alphatec Q1 revenue up 54% to $109M; surgical revenue up 55%; adj EBITDA loss -$5M
Total revenue $109M (+54% YoY); surgical revenue +55%; EOS revenue $15M.
Alphatec prices $60M public offering of 4.3M shares at $14.00/share
Gross proceeds ~$60M from 4,285,715 shares priced at $14.00 per share.
Alphatec acquires REMI robotic navigation system for $55M; raises FY2023 revenue guidance to $450M
Acquired REMI Robotic Navigation System assets for $55M cash from Integrity Implants and Fusion Robotics.
Full-year 2022 revenue $351M (+44% YoY); Q4 revenue $106M (+43% YoY).
Full-year 2022 total revenue $350.1M-$351.1M, up ~44% YoY; Q4 revenue $105.2M-$106.2M.
Alphatec Q3 revenue $90M (+43% YoY); surgical revenue +53%; guides FY22 $340M
Total revenue $90M, up 43% YoY; surgical revenue up 53% to $79M; EOS revenue $11M.
ATEC pre-announces Q3 revenue $89-90M (+42-43% YoY) and raises FY22 growth guidance to ~40%
Total revenue $89-90M (organic $78-78.8M) vs. $62.8M in Q3 2021; organic revenue growth 51-53%.
Alphatec enters $50M ABL credit facility; accordion up to $75M, matures 2027
Facility secured by accounts receivable (85% advance rate) and inventory (40%, capped at $15M or 50% of borrowing base).
ATEC Q2 revenue $84M (+35%), raises FY2022 guidance to $325M (+34%)
Total Q2 revenue $84M, up 35% YoY (organic 30%); EOS imaging contributed $12M.
ATEC Q1 revenue $71M (+61% YoY); raises FY22 guidance to $316M
Total revenue $71M, up 61% YoY (organic 39%); GAAP gross margin 69%, non-GAAP 72%.
ATEC reports record FY2021 revenue of $243.2M, up 68%; guides FY2022 to $305M
Q4 revenue $74.0M; FY2021 revenue $243.2M, up 68% YoY (organic growth 50%).
ATEC preliminary FY2021 US organic revenue growth 50-51%; FY2022 total revenue guidance $305M (+26%)
Preliminary Q4 2021 total revenue $73.2M-$74.0M, US organic rev growth 41-42% YoY.
Alphatec Q3 revenue $62.9M (+53% total, +29% organic); FY21 rev guidance ~$235M (+62%)
Q3 total revenue $62.9M, up 53% YoY; organic revenue rose 29%; GAAP operating loss $35.1M.
Effective July 29, 2024, the Company's Board of Directors (“Board”) increased the number of directors to serve on the Board to ten members and appointed Keith Valentine to serve as a director of the Company
Elizabeth Altman, Marie Meynadier, David Mowry and James Tullis were not nominated for re-election at the Annual Meeting and, as such, each of their respective terms as directors concluded following the Annual Meeting.
Elizabeth Altman, Marie Meynadier, David Mowry and James Tullis were not nominated for re-election at the Annual Meeting and, as such, each of their respective terms as directors concluded following the Annual Meeting.
Elizabeth Altman, Marie Meynadier, David Mowry and James Tullis were not nominated for re-election at the Annual Meeting and, as such, each of their respective terms as directors concluded following the Annual Meeting.
Elizabeth Altman, Marie Meynadier, David Mowry and James Tullis were not nominated for re-election at the Annual Meeting and, as such, each of their respective terms as directors concluded following the Annual Meeting.
On January 1, 2024, Alphatec Holdings, Inc. (the “Company”) promoted Scott Lish to Chief Operating Officer.
On October 16, 2023, the Board of Directors of Alphatec Holdings Inc. (the "Board") appointed Dave Demski to serve as a director of Alphatec Holdings, Inc. (the "Company") for a term commencing on October 17, 2023 and expiring at the Annual Meeting of Stockholders of the Company in 2024 and until his successor is duly elected and qualifies, unless he sooner dies, retires or resigns.
Mr. Hunsaker stepped down from his role as the Company’s General Counsel and Corporate Secretary, effective as of July 19, 2023.
On July 19, 2023, the Company appointed Tyson Marshall as the Company’s General Counsel and Corporate Secretary, effective immediately.
On July 22, 2021, the Board appointed Beth Altman to fill the vacancy created by Mr. Williams’s resignation to serve as a director of the Company and as Chair of the Company’s Audit Committee for a term commencing on August 12, 2021.
On July 20, 2021, the Company received written notice from Donald A. Williams of his resignation from the Board of Directors of the Company (the “Board”), effective August 11, 2021.
Max materiality 0.85 · Median 0.75 · Most common event earnings